Docetaxel (T) given concurrently with or sequentially to anthracycline-based (A) adjuvant therapy (adjRx) for patients (pts) with node-positive (N+) breast cancer (BrCa), in comparison with non-T adjRx: First results of the BIG 2-98 Trial at 5 years median follow-up (MFU). - Crown,J.P.; Francis,P.; Di Leo,A.; Buyse,M.; Balil,A.; Anderson,M.; Nordenskjöld,B.; Jakesz,R.; Gutierrez,J.; Piccart,M. (J Clin Oncol, 2006)